Burgeoning evidence supports a causal role for elevated lipoprotein(a) levels in cardiovascular disease. Now, new data from ODYSSEY OUTCOMES show that elevated lipoprotein(a) contributed to the clinical benefit with alirocumab, independent of LDL cholesterol lowering in very high-risk patients with a recent acute coronary syndrome. These findings align with results from FOURIER which showed that patients with established cardiovascular disease with higher baseline lipoprotein(a) levels obtained greater clinical benefit from evolocumab treatment.

Read the report here »

• Identifying highest risk patients for PCSK9 inhibition: ODYSSEY OUTCOMES subgroup analysis highlights polyvascular disease
• More insights from FOURER and TAUSSIG with evolocumab
• LIB003: Novel PCSK9 treatment

View the reports from ACC.19 here »